FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4379285675> ?p ?o ?g. }

• W4379285675 endingPage "e12584" @default.
• W4379285675 startingPage "e12584" @default.
• W4379285675 abstract "e12584 Background: Most chemotherapeutics can improve responses to immune checkpoint inhibitors (ICI) by increased immunogenicity. Anthracycline(AC), taxane(T) and platinum (CDDP) has most direct cytotoxic effect in neoadjuvant chemotherapy (NAC) of triple negative breast cancer (TNBC), but which one deserve the most immunostimulatory activity linked to their capacity of to kill cancer cell still unknown. Methods: A total of 91 patients with complete data of size measurement by ultrasound (US) were identified for the study from 363 consecutive TNBC patients received NAC between November 2010 to August 2022. They were divided into 3 groups. The 1st group patients received AC first, then T with CDDP, 2nd group in reverse sequence (T and CDDP first) and 3rd group, sequence as group 2 but adding ICI (pembrolizumab). Tumors size measured by US before chemotherapy, after 1st and after 2nd regimen of chemotherapy. Percentage of size reduction of tumor maximal diameter (cm), surface area (transverse x longitudinal diameter, cm 2 ) and volume (measured by 1/6 p x transverse x longitudinal x height cm 3 ) were calculated. Statistically significant was calculated using the Mann-Whitney U test for percentage of size reduction and Pearson's chi-squared test for pCR rate, p-value < 0.05 was considered significant. Results: There were 14, 56 and 21 patients in group 1, 2 and 3, respectively. The significant difference of pathologic complete response rates 7.1%, 44.6% and 76.2% in each group as shown. The volume, surface area and maximal tumor size reduction percentage after 1st regimen chemotherapy in group 1 (AC), group 2 (T+CDDP) and group 3 (ICI+T+CDDP) were -67.24, -55.43, -31.13; -85.45, -72.13, -45.61 and -87.13, -69.75, -45.02, respectively, and size reduction after 2nd regimen chemotherapy in group 2 (AC) were, -42.19, -30.19, -21.13; and group 3 (ICI+AC) were -77.78, -50.76, -30.65; respectively. A statistical non-significant trend of greater size reduction in ICI+ AC than AC alone was found. Conclusions: The study is the first, direct evidence demonstrated the synergistic effect of size reduction after NAC for TNBC with AC and ICI, but not T. It supports the potential benefit of combining chemotherapy with immunotherapy such as Tonic trial reported. [Table: see text]" @default.
• W4379285675 created "2023-06-05" @default.
• W4379285675 creator A5000986526 @default.
• W4379285675 creator A5009653018 @default.
• W4379285675 creator A5013543492 @default.
• W4379285675 creator A5031879022 @default.
• W4379285675 creator A5049607266 @default.
• W4379285675 creator A5053209984 @default.
• W4379285675 creator A5058035186 @default.
• W4379285675 creator A5061020921 @default.
• W4379285675 creator A5064202379 @default.
• W4379285675 creator A5075469418 @default.
• W4379285675 creator A5078601141 @default.
• W4379285675 creator A5080116855 @default.
• W4379285675 creator A5089770713 @default.
• W4379285675 creator A5090726034 @default.
• W4379285675 creator A5091105267 @default.
• W4379285675 date "2023-06-01" @default.
• W4379285675 modified "2023-09-25" @default.
• W4379285675 title "Efficacy comparison of anthracycline and taxane when added to immune checkpoint inhibitor in neoadjuvant chemotherapy of triple negative breast cancer: Clinical evidence from size-reduction measurement by ultrasound." @default.
• W4379285675 doi "https://doi.org/10.1200/jco.2023.41.16_suppl.e12584" @default.
• W4379285675 hasPublicationYear "2023" @default.
• W4379285675 type Work @default.
• W4379285675 citedByCount "0" @default.
• W4379285675 crossrefType "journal-article" @default.
• W4379285675 hasAuthorship W4379285675A5000986526 @default.
• W4379285675 hasAuthorship W4379285675A5009653018 @default.
• W4379285675 hasAuthorship W4379285675A5013543492 @default.
• W4379285675 hasAuthorship W4379285675A5031879022 @default.
• W4379285675 hasAuthorship W4379285675A5049607266 @default.
• W4379285675 hasAuthorship W4379285675A5053209984 @default.
• W4379285675 hasAuthorship W4379285675A5058035186 @default.
• W4379285675 hasAuthorship W4379285675A5061020921 @default.
• W4379285675 hasAuthorship W4379285675A5064202379 @default.
• W4379285675 hasAuthorship W4379285675A5075469418 @default.
• W4379285675 hasAuthorship W4379285675A5078601141 @default.
• W4379285675 hasAuthorship W4379285675A5080116855 @default.
• W4379285675 hasAuthorship W4379285675A5089770713 @default.
• W4379285675 hasAuthorship W4379285675A5090726034 @default.
• W4379285675 hasAuthorship W4379285675A5091105267 @default.
• W4379285675 hasConcept C121608353 @default.
• W4379285675 hasConcept C126322002 @default.
• W4379285675 hasConcept C126894567 @default.
• W4379285675 hasConcept C143998085 @default.
• W4379285675 hasConcept C2776694085 @default.
• W4379285675 hasConcept C2776802502 @default.
• W4379285675 hasConcept C2777511904 @default.
• W4379285675 hasConcept C2780110267 @default.
• W4379285675 hasConcept C2781413609 @default.
• W4379285675 hasConcept C2989005 @default.
• W4379285675 hasConcept C530470458 @default.
• W4379285675 hasConcept C71924100 @default.
• W4379285675 hasConcept C90924648 @default.
• W4379285675 hasConceptScore W4379285675C121608353 @default.
• W4379285675 hasConceptScore W4379285675C126322002 @default.
• W4379285675 hasConceptScore W4379285675C126894567 @default.
• W4379285675 hasConceptScore W4379285675C143998085 @default.
• W4379285675 hasConceptScore W4379285675C2776694085 @default.
• W4379285675 hasConceptScore W4379285675C2776802502 @default.
• W4379285675 hasConceptScore W4379285675C2777511904 @default.
• W4379285675 hasConceptScore W4379285675C2780110267 @default.
• W4379285675 hasConceptScore W4379285675C2781413609 @default.
• W4379285675 hasConceptScore W4379285675C2989005 @default.
• W4379285675 hasConceptScore W4379285675C530470458 @default.
• W4379285675 hasConceptScore W4379285675C71924100 @default.
• W4379285675 hasConceptScore W4379285675C90924648 @default.
• W4379285675 hasIssue "16_suppl" @default.
• W4379285675 hasLocation W43792856751 @default.
• W4379285675 hasOpenAccess W4379285675 @default.
• W4379285675 hasPrimaryLocation W43792856751 @default.
• W4379285675 hasRelatedWork W2020150632 @default.
• W4379285675 hasRelatedWork W2152395032 @default.
• W4379285675 hasRelatedWork W2328465541 @default.
• W4379285675 hasRelatedWork W2331329572 @default.
• W4379285675 hasRelatedWork W2591616149 @default.
• W4379285675 hasRelatedWork W3030794620 @default.
• W4379285675 hasRelatedWork W4210351854 @default.
• W4379285675 hasRelatedWork W4292824716 @default.
• W4379285675 hasRelatedWork W4311544009 @default.
• W4379285675 hasRelatedWork W757206253 @default.
• W4379285675 hasVolume "41" @default.
• W4379285675 isParatext "false" @default.
• W4379285675 isRetracted "false" @default.
• W4379285675 workType "article" @default.